Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03662334 · ClinicalTrials.gov registry record · Phase 4
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
A Phase 4 study, sponsored by Halozyme Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT03662334 is a Phase 4 study that has completed, run by Halozyme Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT03662334, a Phase 4 study, has completed, sponsored by Halozyme Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The goal of this study is to determine if Hylenex recombinant leads to changes in the insulin time-action profiles and glucose responses when preadministered in the setting of continuous subcutaneous insulin infusion (CSII) compared to CSII without Hylenex recombinant (sham injection).
Interventions
- DRUG Rapid Acting insulin with pre-treatment of rHuPH20
- DEVICE Sham injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-10-03 |
| Est. Completion | 2014-02-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03662334
The ClinicalTrials.gov registry entry for NCT03662334 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Halozyme Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rapid Acting insulin with pre-treatment of rHuPH20 is the first listed.
NCT03662334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03662334 about?
NCT03662334 is a clinical study titled "A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)". The goal of this study is to determine if Hylenex recombinant leads to changes in the insulin time-action profiles and glucose responses when preadministered in the setting of continuous subcutaneous insulin infusion (CSII) compared to CSII without Hylenex recombinant (sham injection).
What is the current status of trial NCT03662334?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2013-10-03. Estimated completion is 2014-02-27.
What interventions are being tested in trial NCT03662334?
The interventions under investigation include: Rapid Acting insulin with pre-treatment of rHuPH20 (DRUG), Sham injection (DEVICE).
Who is sponsoring clinical trial NCT03662334?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.